论文部分内容阅读
星形细胞瘤是颅内常见原发肿瘤,其治疗方法由单一手术治疗发展为手术加放疗和化疗等综合疗法,但患者预后并未明显改善。病理分期是星形细胞瘤重要的预后指标,但相同病理分期且接受相同治疗的患者预后仍有不同。因此,临床需要新的可与病理分期相结合的分子预后标志物来指导诊断和治疗。本文就星形细胞瘤分子生物学预后标志物的研究进展及其临床意义进行综述。
Astrocytoma is a common intracranial tumor, the treatment of which developed from a single surgical treatment combined with radiotherapy and chemotherapy and other comprehensive treatment, but the prognosis of patients did not significantly improved. Pathological staging is an important prognostic indicator of astrocytoma, but patients with the same pathologic stage and receiving the same treatment have different prognoses. Therefore, the clinical need for new pathological staging combined molecular prognostic markers to guide the diagnosis and treatment. This article summarizes the research progress and clinical significance of molecular prognostic markers of astrocytoma.